Phase III FURI study of ibrexafungerp shows positive clinical results in multiple fungal infections – Scynexis
Scynexis announced an oral presentation of analyses of interim data from its ongoing Phase III FURI study showing favorable clinical activity of oral Brexafemme (ibrexafungerp) in severe hospital-based… read more.
